Patient–physician communication and health-related quality of life of patients with localised prostate cancer undergoing radical prostatectomy – a longitudinal multilevel analysis

BJU International

Volumn 119, Issue 3, 2017, Pages 396-405

  Ernstmann, Nicole ^a   Weissbach, Lothar ^b   Herden, Jan ^c   Winter, Nicola ^c   Ansmann, Lena ^d  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b Stiftung Maennergesundheit   (Germany)

^c UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^d UNIVERSITY OF COLOGNE   (Germany)

Author keywords

communication; health related quality of life; localised prostate cancer; prostatectomy; psychosocial needs

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER EPIDEMIOLOGY; CANCER HORMONE THERAPY; CHARLSON COMORBIDITY INDEX; CONTROLLED STUDY; CORRELATION COEFFICIENT; DOCTOR PATIENT RELATION; EMOTIONALITY; HUMAN; LIFE EXPECTANCY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; QUESTIONNAIRE; MIDDLE AGED; MULTILEVEL ANALYSIS; PATHOLOGY; PROCEDURES; PROSTATIC NEOPLASMS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTILEVEL ANALYSIS; PHYSICIAN-PATIENT RELATIONS; PROSPECTIVE STUDIES; PROSTATECTOMY; PROSTATIC NEOPLASMS; QUALITY OF LIFE;

EID: 85012877605     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.13495     Document Type: Article

References (54)

1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013; 49: 1374–403
2. Batzler WU, Giersiepen K, Hentschel S et al. Krebs in Deutschland 2003–2004: Häufigkeiten und Trends. Berlin; 2008. (Beiträge zur Gesundheitsberichterstattung des Bundes; vol. 6). Available at: http://edoc.rki.de/documents/rki_fv/reJBwqKp45PiI/PDF/24aj8tYVir1Lo_08.pdf. Accessed April 2016
3. Walz J, Gallina A, Saad F et al. A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer. J Clin Oncol 2007; 25: 3576–81
4. Bill-Axelson A, Holmberg L, Garmo H et al. Radical Prostatectomy or watchful waiting in early prostate cancer. N Engl J Med 2014; 370: 932–42
5. Wilt TJ, Brawer MK, Jones KM et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012; 367: 203–13
6. Albertsen PC, Hanley JA, Penson DF, Barrows G, Fine J. 13-year outcomes following treatment for clinically localized prostate cancer in a population based cohort. J Urol 2007; 177: 932–6
7. Klotz L, Vesprini D, Sethukavalan P et al. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol 2015; 33: 272–7
8. Kweldam CF, Wildhagen MF, Bangma CH, van Leenders GJ. Disease-specific death and metastasis do not occur in patients with Gleason score ≤6 at radical prostatectomy. BJU Int 2015; 116: 230–5
9. Steginga SK, Occhipinti S, Gardiner RA, Yaxley J, Heathcote P. Prospective study of men's psychological and decision-related adjustment after treatment for localized prostate cancer. Urology 2004; 63: 751–6
10. Steginga SK, Turner E, Donovan J. The decision-related psychosocial concerns of men with localised prostate cancer: targets for intervention and research. World J Urol 2008; 26: 469–74
11. Bisson JI, Chubb HL, Bennett S, Mason M, Jones D, Kynaston H. The prevalence and predictors of psychological distress in patients with early localized prostate cancer. BJU Int 2002; 90: 56–61
12. Perez MA, Skinner EC, Meyerowitz BE. Sexuality and intimacy following radical prostatectomy: patient and partner perspectives. Health Psychol 2002; 21: 288–93
13. Watts S, Leydon G, Birch B et al. Depression and anxiety in prostate cancer: a systematic review and meta-analysis of prevalence rates. BMJ Open 2014; 4: e003901
14. Orom H, Nelson CJ, Underwood W 3rd, Homish DL, Kapoor DA. Factors associated with emotional distress in newly diagnosed prostate cancer patients. Psychooncology 2015; 24: 1416–22
15. Orom H, Penner LA, West BT, Downs TM, Rayford W, Underwood W. Personality predicts prostate cancer treatment decision-making difficulty and satisfaction. Psychooncology 2009; 18: 290–9
16. Feldman-Stewart D, Brundage MD, Hayter C et al. What questions do patients with curable prostate cancer want answered? Med Decis Making 2000; 20: 7–19
17. Feldman-Stewart D, Capirci C, Brennenstuhl S et al. Information needs of early-stage prostate cancer patients: a comparison of nine countries. Radiother Oncol 2010; 94: 328–33
18. Boberg EW, Gustafson DH, Hawkins RP et al. Assessing the unmet information, support and care delivery needs of men with prostate cancer. Patient Educ Couns 2003; 49: 233–42
19. Steginga SK, Occhipinti S, Dunn J, Gardiner RA, Heathcote P, Yaxley J. The supportive care needs of men with prostate cancer (2000). Psychooncology 2001; 10: 66–75
20. Lintz K, Moynihan C, Steginga S et al. Prostate cancer patients’ support and psychological care needs: survey from a non-surgical oncology clinic. Psychooncology 2003; 12: 769–83
21. Shapiro P, Coyne J, Kruss L, Palmers SC, Vaugh DJ, Malkowicz B. Interest in services among prostate cancer patients receiving androgen deprivation therapy. Psychooncology 2004; 13: 512–25
22. Voerman B, Visser A, Fischer M, Garssen B, van Andel G, Bensing J. Determinants of participation in social support groups for prostate cancer patients. Psychooncology 2007; 16: 1092–9
23. Davison BJ, Parker PA, Goldenberg SL. Patients’ preferences for communicating a prostate cancer diagnosis and participating in medical decision-making. BJU Int 2004; 93: 47–51
24. Holmboe ES, Concato J. Treatment decisions for localized prostate cancer: asking men what's important. J Gen Intern Med 2000; 15: 694–701
25. Steginga SK, Occhipinti S, Gardiner RA, Yaxley J, Heathcote P. Making decisions about treatment for localized prostate cancer. BJU Int 2002; 89: 255–60
26. Mazur DJ, Hickam DH. Patient preferences for management of localized prostate cancer. West J Med 1996; 165: 26–30
27. van Tol-Geerdink JJ, Stalmeier PF, van Lin Emile EN et al. Do patients with localized prostate cancer treatment really want more aggressive treatment? J Clin Oncol 2006; 24: 4581–6
28. Sharpley CF, Christie DRH. Patient information preferences among breast and prostate cancer patients. Australas Radiol 2007; 51: 154–8
29. Prabhu V, Lee T, McClintock TR, Lepor H. Short-, intermediate-, and long-term quality of life outcomes following radical prostatectomy for clinically localized prostate cancer. Rev Urol 2013; 15: 161–77
30. Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A. The EORTC QLQ-C30 Scoring Manual, 3rd edn. Brüssel: European Organization for Research and Treatment of Cancer, 2001. (3rd). Available at: http://www.eortc.be/qol/files/SCManualQLQ-C30.pdf. Accessed April 2016
31. Herkommer K, Schmid SC, Schulwitz H et al. Health-related quality of life after radical prostatectomy depends on patient‏d. age but not on comorbidities. Urol Oncol 2015;33:266.
32. Hampson LA, Cowan JE, Zhao S, Carroll PR, Cooperberg MR. Impact of age on quality-of-life outcomes after treatment for localized prostate cancer. Eur Urol 2015; 68: 480–6
33. Namiki S, Kaiho Y, Mitsuzuka K et al. Long-term quality of life after radical prostatectomy: 8-year longitudinal study in Japan. Int J Urol 2014; 21: 1220–6
34. Neumann M, Edelhäuser F, Kreps GL et al. Can patient-provider interaction increase the effectiveness of medical treatment or even substitute it? an exploration on why and how to study the specific effect of the provider. Patient Educ Couns 2010; 80: 307–14
35. Neumann M, Wirtz M, Bollschweiler E et al. Determinants and patient-reported long-term outcomes of physician empathy in oncology: a structural equation modelling approach. Patient Educ Couns 2007; 69: 63–75
36. Ommen O, Wirtz M, Janßen C et al. Psychometric evaluation of an instrument to assess patient-reported ‘psychosocial care by physicians’: a structural equation modeling approach. Int J Qual Health Care 2009; 21: 190–7
37. Ommen O, Wirtz M, Janßen C, Neumann M, Ernstmann N, Pfaff H. Validation of a theory-based instrument measuring patient-reported psychosocial care by physicians using a multiple indicators and multiple causes model. Patient Educ Couns 2010; 80: 100–6
38. Ernstmann N, Ommen O, Kowalski C et al. A longitudinal study of changes in provider-patient interaction in treatment of localized prostate cancer. Support Care Cancer 2012; 20: 791–7
39. D'Amico AV, Whittington R, Malkowicz SB et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969–74
40. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373–83
41. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol 1994; 47: 1245–51
42. Kwok O, Underhill AT, Berry JW, Luo W, Elliott TR, Yoon M. Analyzing longitudinal data with multilevel models: an example with individuals living with lower extremity intra-articular fractures. Rehabil Psychol 2008; 53: 370–86
43. Twisk JW. Applied Multilevel Analysis: a practical guide, Cambridge: Cambridge University Press: 2006
44. Hox JJ. Multilevel Analysis: techniques and applications, 2nd edn. (Quantitative methodology series; vol. 2). New York: Routledge, 2010
45. Kreft IG, deLeeuw J.Introducing Multilevel Modeling. Introducing Statistical Methods series, 6, London: Sage Publications, 2007
46. Schwarz R, Hinz A. Reference data for the quality of life questionnaire EORTC QLQ-C30 in the general German population. Eur J Cancer 2001; 37: 1345–51
47. Salmon P, Young B. Dependence and caring in clinical communication: the relevance of attachment and other theories. Patient Educ Couns 2009; 74: 331–8
48. Song L, Mishel M, Bensen JT et al. How does health literacy affect quality of life among men with newly diagnosed clinically localized prostate cancer? Findings from the North Carolina-Louisiana Prostate Cancer Project (PCaP). Cancer 2012; 118: 3842–51
49. Maly RC1, Liu Y, Liang LJ, Ganz PA. Quality of life over 5 years after a breast cancer diagnosis among low-income women: effects of race/ethnicity and patient-physician communication. Cancer 2015;121:916–26.
50. Kerr J, Engel J, Schlesinger-Raab A, Sauer H, Hoelzel D. Communication, quality of life and age: results of a 5-year prospective study in breast cancer patients. Ann Oncol 2003; 14: 421–7
51. Hamidou Z, Dabakuyo TS, Bonnetain F. Impact of response shift on longitudinal quality-of-life assessment in cancer clinical trials. Expert Rev Pharmacoecon Outcomes Res 2011; 11: 549–59
52. Osoba D, Tannock IF, Ernst DS, Neville AJ. Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J Clin Oncol 1999; 17: 1654–63
53. King CR, Collins S, Fuller D et al. Health-related quality of life after stereotactic body radiation therapy for localized prostate cancer: results from a multi-institutional consortium of prospective trials. Int J Radiat Oncol Biol Phys 2013; 87: 939–45
54. Pinkawa M, Fischedick K, Gagel B et al. Impact of age and comorbidities on health-related quality of life for patients with prostate cancer: evaluation before a curative treatment. BMC Cancer 2009; 9: 296